Hypersensitivity to the active substance or to any of the excipients listed in Description.
During pregnancy and in women of childbearing potential not using effective contraception (see Precautions and Use in Pregnancy & Lactation).
Concomitant treatment with strong CYP3A4 inhibitors in patients with CYP2C19 poor metaboliser phenotype and undetermined CYP2C19 phenotype (see Dosage & Administration, Precautions and Interactions).
Concomitant treatment with the combination of a strong CYP2C19 inhibitor and a strong CYP3A4 inhibitor (see Interactions).